The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Duchenne Muscular Dystrophy Market Research Report 2025
Synopsis
The global market for Duchenne Muscular Dystrophy was valued at US$ 2267 million in the year 2024 and is projected to reach a revised size of US$ 25740 million by 2031, growing at a CAGR of 42.1% during the forecast period.
uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys" respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.
Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc.
North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent.
In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy.
The Duchenne Muscular Dystrophy market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Duchenne Muscular Dystrophy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Duchenne Muscular Dystrophy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
Segment by Type
Exondys 51
Emflaza
Translarna
Segment by Application
Hospitals
Clinics
Home Care
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Duchenne Muscular Dystrophy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Duchenne Muscular Dystrophy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global market for Duchenne Muscular Dystrophy was valued at US$ 2267 million in the year 2024 and is projected to reach a revised size of US$ 25740 million by 2031, growing at a CAGR of 42.1% during the forecast period.
uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys" respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.
Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc.
North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent.
In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy.
The Duchenne Muscular Dystrophy market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Duchenne Muscular Dystrophy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Duchenne Muscular Dystrophy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
Segment by Type
Exondys 51
Emflaza
Translarna
Segment by Application
Hospitals
Clinics
Home Care
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Duchenne Muscular Dystrophy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Duchenne Muscular Dystrophy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Duchenne Muscular Dystrophy Market Overview
1.1 Product Definition
1.2 Duchenne Muscular Dystrophy by Type
1.2.1 Global Duchenne Muscular Dystrophy Market Value Comparison by Type (2024 VS 2031)
1.2.2 Exondys 51
1.2.3 Emflaza
1.2.4 Translarna
1.3 Duchenne Muscular Dystrophy by Application
1.3.1 Global Duchenne Muscular Dystrophy Market Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Global Duchenne Muscular Dystrophy Market Size Estimates and Forecasts
1.4.1 Global Duchenne Muscular Dystrophy Revenue 2020-2031
1.4.2 Global Duchenne Muscular Dystrophy Sales 2020-2031
1.4.3 Global Duchenne Muscular Dystrophy Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Duchenne Muscular Dystrophy Market Competition by Manufacturers
2.1 Global Duchenne Muscular Dystrophy Sales Market Share by Manufacturers (2020-2025)
2.2 Global Duchenne Muscular Dystrophy Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Duchenne Muscular Dystrophy Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Duchenne Muscular Dystrophy, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Duchenne Muscular Dystrophy, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Duchenne Muscular Dystrophy, Product Type & Application
2.7 Global Key Manufacturers of Duchenne Muscular Dystrophy, Date of Enter into This Industry
2.8 Global Duchenne Muscular Dystrophy Market Competitive Situation and Trends
2.8.1 Global Duchenne Muscular Dystrophy Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Duchenne Muscular Dystrophy Players Market Share by Revenue
2.8.3 Global Duchenne Muscular Dystrophy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Duchenne Muscular Dystrophy Market Scenario by Region
3.1 Global Duchenne Muscular Dystrophy Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Duchenne Muscular Dystrophy Sales by Region: 2020-2031
3.2.1 Global Duchenne Muscular Dystrophy Sales by Region: 2020-2025
3.2.2 Global Duchenne Muscular Dystrophy Sales by Region: 2026-2031
3.3 Global Duchenne Muscular Dystrophy Revenue by Region: 2020-2031
3.3.1 Global Duchenne Muscular Dystrophy Revenue by Region: 2020-2025
3.3.2 Global Duchenne Muscular Dystrophy Revenue by Region: 2026-2031
3.4 North America Duchenne Muscular Dystrophy Market Facts & Figures by Country
3.4.1 North America Duchenne Muscular Dystrophy Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Duchenne Muscular Dystrophy Sales by Country (2020-2031)
3.4.3 North America Duchenne Muscular Dystrophy Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Duchenne Muscular Dystrophy Market Facts & Figures by Country
3.5.1 Europe Duchenne Muscular Dystrophy Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Duchenne Muscular Dystrophy Sales by Country (2020-2031)
3.5.3 Europe Duchenne Muscular Dystrophy Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Duchenne Muscular Dystrophy Market Facts & Figures by Region
3.6.1 Asia Pacific Duchenne Muscular Dystrophy Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Duchenne Muscular Dystrophy Sales by Region (2020-2031)
3.6.3 Asia Pacific Duchenne Muscular Dystrophy Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Duchenne Muscular Dystrophy Market Facts & Figures by Country
3.7.1 Latin America Duchenne Muscular Dystrophy Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Duchenne Muscular Dystrophy Sales by Country (2020-2031)
3.7.3 Latin America Duchenne Muscular Dystrophy Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Duchenne Muscular Dystrophy Market Facts & Figures by Country
3.8.1 Middle East and Africa Duchenne Muscular Dystrophy Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2020-2031)
3.8.3 Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Duchenne Muscular Dystrophy Sales by Type (2020-2031)
4.1.1 Global Duchenne Muscular Dystrophy Sales by Type (2020-2025)
4.1.2 Global Duchenne Muscular Dystrophy Sales by Type (2026-2031)
4.1.3 Global Duchenne Muscular Dystrophy Sales Market Share by Type (2020-2031)
4.2 Global Duchenne Muscular Dystrophy Revenue by Type (2020-2031)
4.2.1 Global Duchenne Muscular Dystrophy Revenue by Type (2020-2025)
4.2.2 Global Duchenne Muscular Dystrophy Revenue by Type (2026-2031)
4.2.3 Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2020-2031)
4.3 Global Duchenne Muscular Dystrophy Price by Type (2020-2031)
5 Segment by Application
5.1 Global Duchenne Muscular Dystrophy Sales by Application (2020-2031)
5.1.1 Global Duchenne Muscular Dystrophy Sales by Application (2020-2025)
5.1.2 Global Duchenne Muscular Dystrophy Sales by Application (2026-2031)
5.1.3 Global Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2031)
5.2 Global Duchenne Muscular Dystrophy Revenue by Application (2020-2031)
5.2.1 Global Duchenne Muscular Dystrophy Revenue by Application (2020-2025)
5.2.2 Global Duchenne Muscular Dystrophy Revenue by Application (2026-2031)
5.2.3 Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2020-2031)
5.3 Global Duchenne Muscular Dystrophy Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Sarepta Therapeutics
6.1.1 Sarepta Therapeutics Company Information
6.1.2 Sarepta Therapeutics Description and Business Overview
6.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Product Portfolio
6.1.5 Sarepta Therapeutics Recent Developments/Updates
6.2 PTC Therapeutics
6.2.1 PTC Therapeutics Company Information
6.2.2 PTC Therapeutics Description and Business Overview
6.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2020-2025)
6.2.4 PTC Therapeutics Duchenne Muscular Dystrophy Product Portfolio
6.2.5 PTC Therapeutics Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Company Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Pfizer Duchenne Muscular Dystrophy Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Bristol-Myers Squibb
6.4.1 Bristol-Myers Squibb Company Information
6.4.2 Bristol-Myers Squibb Description and Business Overview
6.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolio
6.4.5 Bristol-Myers Squibb Recent Developments/Updates
6.5 Italfarmaco
6.5.1 Italfarmaco Company Information
6.5.2 Italfarmaco Description and Business Overview
6.5.3 Italfarmaco Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Italfarmaco Duchenne Muscular Dystrophy Product Portfolio
6.5.5 Italfarmaco Recent Developments/Updates
6.6 Santhera Pharmaceuticals
6.6.1 Santhera Pharmaceuticals Company Information
6.6.2 Santhera Pharmaceuticals Description and Business Overview
6.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolio
6.6.5 Santhera Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Duchenne Muscular Dystrophy Industry Chain Analysis
7.2 Duchenne Muscular Dystrophy Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Duchenne Muscular Dystrophy Production Mode & Process Analysis
7.4 Duchenne Muscular Dystrophy Sales and Marketing
7.4.1 Duchenne Muscular Dystrophy Sales Channels
7.4.2 Duchenne Muscular Dystrophy Distributors
7.5 Duchenne Muscular Dystrophy Customer Analysis
8 Duchenne Muscular Dystrophy Market Dynamics
8.1 Duchenne Muscular Dystrophy Industry Trends
8.2 Duchenne Muscular Dystrophy Market Drivers
8.3 Duchenne Muscular Dystrophy Market Challenges
8.4 Duchenne Muscular Dystrophy Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Duchenne Muscular Dystrophy Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Duchenne Muscular Dystrophy Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Duchenne Muscular Dystrophy Market Competitive Situation by Manufacturers in 2024
Table 4. Global Duchenne Muscular Dystrophy Sales (K Doses) of Key Manufacturers (2020-2025)
Table 5. Global Duchenne Muscular Dystrophy Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Duchenne Muscular Dystrophy Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Duchenne Muscular Dystrophy Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Duchenne Muscular Dystrophy Average Price (USD/Dose) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Duchenne Muscular Dystrophy, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Duchenne Muscular Dystrophy, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Duchenne Muscular Dystrophy, Product Type & Application
Table 12. Global Key Manufacturers of Duchenne Muscular Dystrophy, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Duchenne Muscular Dystrophy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Duchenne Muscular Dystrophy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Duchenne Muscular Dystrophy Sales by Region (2020-2025) & (K Doses)
Table 18. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2020-2025)
Table 19. Global Duchenne Muscular Dystrophy Sales by Region (2026-2031) & (K Doses)
Table 20. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2026-2031)
Table 21. Global Duchenne Muscular Dystrophy Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2020-2025)
Table 23. Global Duchenne Muscular Dystrophy Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2026-2031)
Table 25. North America Duchenne Muscular Dystrophy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Duchenne Muscular Dystrophy Sales by Country (2020-2025) & (K Doses)
Table 27. North America Duchenne Muscular Dystrophy Sales by Country (2026-2031) & (K Doses)
Table 28. North America Duchenne Muscular Dystrophy Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Duchenne Muscular Dystrophy Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Duchenne Muscular Dystrophy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Duchenne Muscular Dystrophy Sales by Country (2020-2025) & (K Doses)
Table 32. Europe Duchenne Muscular Dystrophy Sales by Country (2026-2031) & (K Doses)
Table 33. Europe Duchenne Muscular Dystrophy Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Duchenne Muscular Dystrophy Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Duchenne Muscular Dystrophy Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Duchenne Muscular Dystrophy Sales by Region (2020-2025) & (K Doses)
Table 37. Asia Pacific Duchenne Muscular Dystrophy Sales by Region (2026-2031) & (K Doses)
Table 38. Asia Pacific Duchenne Muscular Dystrophy Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Duchenne Muscular Dystrophy Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Duchenne Muscular Dystrophy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Duchenne Muscular Dystrophy Sales by Country (2020-2025) & (K Doses)
Table 42. Latin America Duchenne Muscular Dystrophy Sales by Country (2026-2031) & (K Doses)
Table 43. Latin America Duchenne Muscular Dystrophy Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Duchenne Muscular Dystrophy Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2020-2025) & (K Doses)
Table 47. Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2026-2031) & (K Doses)
Table 48. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Duchenne Muscular Dystrophy Sales (K Doses) by Type (2020-2025)
Table 51. Global Duchenne Muscular Dystrophy Sales (K Doses) by Type (2026-2031)
Table 52. Global Duchenne Muscular Dystrophy Sales Market Share by Type (2020-2025)
Table 53. Global Duchenne Muscular Dystrophy Sales Market Share by Type (2026-2031)
Table 54. Global Duchenne Muscular Dystrophy Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Duchenne Muscular Dystrophy Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2020-2025)
Table 57. Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2026-2031)
Table 58. Global Duchenne Muscular Dystrophy Price (USD/Dose) by Type (2020-2025)
Table 59. Global Duchenne Muscular Dystrophy Price (USD/Dose) by Type (2026-2031)
Table 60. Global Duchenne Muscular Dystrophy Sales (K Doses) by Application (2020-2025)
Table 61. Global Duchenne Muscular Dystrophy Sales (K Doses) by Application (2026-2031)
Table 62. Global Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2025)
Table 63. Global Duchenne Muscular Dystrophy Sales Market Share by Application (2026-2031)
Table 64. Global Duchenne Muscular Dystrophy Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Duchenne Muscular Dystrophy Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2020-2025)
Table 67. Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2026-2031)
Table 68. Global Duchenne Muscular Dystrophy Price (USD/Dose) by Application (2020-2025)
Table 69. Global Duchenne Muscular Dystrophy Price (USD/Dose) by Application (2026-2031)
Table 70. Sarepta Therapeutics Company Information
Table 71. Sarepta Therapeutics Description and Business Overview
Table 72. Sarepta Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 73. Sarepta Therapeutics Duchenne Muscular Dystrophy Product
Table 74. Sarepta Therapeutics Recent Developments/Updates
Table 75. PTC Therapeutics Company Information
Table 76. PTC Therapeutics Description and Business Overview
Table 77. PTC Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 78. PTC Therapeutics Duchenne Muscular Dystrophy Product
Table 79. PTC Therapeutics Recent Developments/Updates
Table 80. Pfizer Company Information
Table 81. Pfizer Description and Business Overview
Table 82. Pfizer Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 83. Pfizer Duchenne Muscular Dystrophy Product
Table 84. Pfizer Recent Developments/Updates
Table 85. Bristol-Myers Squibb Company Information
Table 86. Bristol-Myers Squibb Description and Business Overview
Table 87. Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 88. Bristol-Myers Squibb Duchenne Muscular Dystrophy Product
Table 89. Bristol-Myers Squibb Recent Developments/Updates
Table 90. Italfarmaco Company Information
Table 91. Italfarmaco Description and Business Overview
Table 92. Italfarmaco Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 93. Italfarmaco Duchenne Muscular Dystrophy Product
Table 94. Italfarmaco Recent Developments/Updates
Table 95. Santhera Pharmaceuticals Company Information
Table 96. Santhera Pharmaceuticals Description and Business Overview
Table 97. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 98. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product
Table 99. Santhera Pharmaceuticals Recent Developments/Updates
Table 100. Key Raw Materials Lists
Table 101. Raw Materials Key Suppliers Lists
Table 102. Duchenne Muscular Dystrophy Distributors List
Table 103. Duchenne Muscular Dystrophy Customers List
Table 104. Duchenne Muscular Dystrophy Market Trends
Table 105. Duchenne Muscular Dystrophy Market Drivers
Table 106. Duchenne Muscular Dystrophy Market Challenges
Table 107. Duchenne Muscular Dystrophy Market Restraints
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
Table 111. Authors List of This Report
List of Figures
Figure 1. Product Picture of Duchenne Muscular Dystrophy
Figure 2. Global Duchenne Muscular Dystrophy Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Duchenne Muscular Dystrophy Market Share by Type: 2024 & 2031
Figure 4. Exondys 51 Product Picture
Figure 5. Emflaza Product Picture
Figure 6. Translarna Product Picture
Figure 7. Global Duchenne Muscular Dystrophy Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Duchenne Muscular Dystrophy Market Share by Application: 2024 & 2031
Figure 9. Hospitals
Figure 10. Clinics
Figure 11. Home Care
Figure 12. Global Duchenne Muscular Dystrophy Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Duchenne Muscular Dystrophy Market Size (2020-2031) & (US$ Million)
Figure 14. Global Duchenne Muscular Dystrophy Sales (2020-2031) & (K Doses)
Figure 15. Global Duchenne Muscular Dystrophy Average Price (USD/Dose) & (2020-2031)
Figure 16. Duchenne Muscular Dystrophy Report Years Considered
Figure 17. Duchenne Muscular Dystrophy Sales Share by Manufacturers in 2024
Figure 18. Global Duchenne Muscular Dystrophy Revenue Share by Manufacturers in 2024
Figure 19. Global 5 and 10 Largest Duchenne Muscular Dystrophy Players: Market Share by Revenue in Duchenne Muscular Dystrophy in 2024
Figure 20. Duchenne Muscular Dystrophy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global Duchenne Muscular Dystrophy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. North America Duchenne Muscular Dystrophy Sales Market Share by Country (2020-2031)
Figure 23. North America Duchenne Muscular Dystrophy Revenue Market Share by Country (2020-2031)
Figure 24. U.S. Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Canada Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Europe Duchenne Muscular Dystrophy Sales Market Share by Country (2020-2031)
Figure 27. Europe Duchenne Muscular Dystrophy Revenue Market Share by Country (2020-2031)
Figure 28. Germany Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. France Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. U.K. Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Italy Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Russia Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Asia Pacific Duchenne Muscular Dystrophy Sales Market Share by Region (2020-2031)
Figure 34. Asia Pacific Duchenne Muscular Dystrophy Revenue Market Share by Region (2020-2031)
Figure 35. China Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Japan Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. South Korea Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. India Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Australia Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. Taiwan Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Indonesia Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Thailand Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Malaysia Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Philippines Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Latin America Duchenne Muscular Dystrophy Sales Market Share by Country (2020-2031)
Figure 46. Latin America Duchenne Muscular Dystrophy Revenue Market Share by Country (2020-2031)
Figure 47. Mexico Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Brazil Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Argentina Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share by Country (2020-2031)
Figure 51. Middle East and Africa Duchenne Muscular Dystrophy Revenue Market Share by Country (2020-2031)
Figure 52. Turkey Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Saudi Arabia Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. U.A.E Duchenne Muscular Dystrophy Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Global Sales Market Share of Duchenne Muscular Dystrophy by Type (2020-2031)
Figure 56. Global Revenue Market Share of Duchenne Muscular Dystrophy by Type (2020-2031)
Figure 57. Global Duchenne Muscular Dystrophy Price (USD/Dose) by Type (2020-2031)
Figure 58. Global Sales Market Share of Duchenne Muscular Dystrophy by Application (2020-2031)
Figure 59. Global Revenue Market Share of Duchenne Muscular Dystrophy by Application (2020-2031)
Figure 60. Global Duchenne Muscular Dystrophy Price (USD/Dose) by Application (2020-2031)
Figure 61. Duchenne Muscular Dystrophy Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
